Cargando…

Continuity of care and advanced prostate cancer

BACKGROUND: Continuity of care is an important element of advanced prostate cancer care due to the availability of multiple treatment options, and associated toxicity. However, the association between continuity of care and outcomes across different racial groups remains unclear. OBJECTIVE: To asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayadevappa, Ravishankar, Guzzo, Thomas, Vapiwala, Neha, Malkowicz, Stanley Bruce, Gallo, Joseph J., Chhatre, Sumedha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242338/
https://www.ncbi.nlm.nih.gov/pubmed/36951508
http://dx.doi.org/10.1002/cam4.5845
_version_ 1785054194296684544
author Jayadevappa, Ravishankar
Guzzo, Thomas
Vapiwala, Neha
Malkowicz, Stanley Bruce
Gallo, Joseph J.
Chhatre, Sumedha
author_facet Jayadevappa, Ravishankar
Guzzo, Thomas
Vapiwala, Neha
Malkowicz, Stanley Bruce
Gallo, Joseph J.
Chhatre, Sumedha
author_sort Jayadevappa, Ravishankar
collection PubMed
description BACKGROUND: Continuity of care is an important element of advanced prostate cancer care due to the availability of multiple treatment options, and associated toxicity. However, the association between continuity of care and outcomes across different racial groups remains unclear. OBJECTIVE: To assess the association of provider continuity of care with outcomes among Medicare fee‐for‐service beneficiaries with advanced prostate cancer and its variation by race. DESIGN: Retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER)‐Medicare data. SUBJECTS: African American and white Medicare beneficiaries aged 66 or older, and diagnosed with advanced prostate cancer between 2000 and 2011. At least 5 years of follow‐up data for the cohort was used. MEASURES: Short‐term outcomes were emergency room (ER) visits, hospitalizations, and cost during acute survivorship phase (2‐year post‐diagnosis), and mortality (all‐cause and prostate cancer‐specific) during the follow‐up period. We calculated continuity of care using Continuity of Care Index (COCI) and Usual Provider Care Index (UPCI), for all visits, oncology visits, and primary care visits in acute survivorship phase. We used Poisson models for ER visits and hospitalizations, and log‐link GLM for cost. Cox model and Fine‐Gray competing risk models were used for survival analysis, weighted by propensity score. We performed similar analysis for continuity of care in the 2‐year period following acute survivorship phase. RESULTS: One unit increase in COCI was associated with reduction in short‐term ER visits (incidence rate ratio [IRR] = 0.65, 95% confidence interval [CI] 0.64, 0.67), hospitalizations (IRR = 0.65, 95% CI 0.64, 0.67), and cost (0.64, 95% CI 0.61, 0.66) and lower hazard of long‐term mortality. Magnitude of these associations differed between African American and white patients. We observed comparable results for continuity of care in the follow‐up period. CONCLUSIONS: Continuity of care was associated with improved outcomes. The benefits of higher continuity of care were greater for African Americans, compared to white patients. Advanced prostate cancer survivorship care must integrate appropriate strategies to promote continuity of care.
format Online
Article
Text
id pubmed-10242338
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102423382023-06-07 Continuity of care and advanced prostate cancer Jayadevappa, Ravishankar Guzzo, Thomas Vapiwala, Neha Malkowicz, Stanley Bruce Gallo, Joseph J. Chhatre, Sumedha Cancer Med RESEARCH ARTICLES BACKGROUND: Continuity of care is an important element of advanced prostate cancer care due to the availability of multiple treatment options, and associated toxicity. However, the association between continuity of care and outcomes across different racial groups remains unclear. OBJECTIVE: To assess the association of provider continuity of care with outcomes among Medicare fee‐for‐service beneficiaries with advanced prostate cancer and its variation by race. DESIGN: Retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER)‐Medicare data. SUBJECTS: African American and white Medicare beneficiaries aged 66 or older, and diagnosed with advanced prostate cancer between 2000 and 2011. At least 5 years of follow‐up data for the cohort was used. MEASURES: Short‐term outcomes were emergency room (ER) visits, hospitalizations, and cost during acute survivorship phase (2‐year post‐diagnosis), and mortality (all‐cause and prostate cancer‐specific) during the follow‐up period. We calculated continuity of care using Continuity of Care Index (COCI) and Usual Provider Care Index (UPCI), for all visits, oncology visits, and primary care visits in acute survivorship phase. We used Poisson models for ER visits and hospitalizations, and log‐link GLM for cost. Cox model and Fine‐Gray competing risk models were used for survival analysis, weighted by propensity score. We performed similar analysis for continuity of care in the 2‐year period following acute survivorship phase. RESULTS: One unit increase in COCI was associated with reduction in short‐term ER visits (incidence rate ratio [IRR] = 0.65, 95% confidence interval [CI] 0.64, 0.67), hospitalizations (IRR = 0.65, 95% CI 0.64, 0.67), and cost (0.64, 95% CI 0.61, 0.66) and lower hazard of long‐term mortality. Magnitude of these associations differed between African American and white patients. We observed comparable results for continuity of care in the follow‐up period. CONCLUSIONS: Continuity of care was associated with improved outcomes. The benefits of higher continuity of care were greater for African Americans, compared to white patients. Advanced prostate cancer survivorship care must integrate appropriate strategies to promote continuity of care. John Wiley and Sons Inc. 2023-03-23 /pmc/articles/PMC10242338/ /pubmed/36951508 http://dx.doi.org/10.1002/cam4.5845 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Jayadevappa, Ravishankar
Guzzo, Thomas
Vapiwala, Neha
Malkowicz, Stanley Bruce
Gallo, Joseph J.
Chhatre, Sumedha
Continuity of care and advanced prostate cancer
title Continuity of care and advanced prostate cancer
title_full Continuity of care and advanced prostate cancer
title_fullStr Continuity of care and advanced prostate cancer
title_full_unstemmed Continuity of care and advanced prostate cancer
title_short Continuity of care and advanced prostate cancer
title_sort continuity of care and advanced prostate cancer
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242338/
https://www.ncbi.nlm.nih.gov/pubmed/36951508
http://dx.doi.org/10.1002/cam4.5845
work_keys_str_mv AT jayadevapparavishankar continuityofcareandadvancedprostatecancer
AT guzzothomas continuityofcareandadvancedprostatecancer
AT vapiwalaneha continuityofcareandadvancedprostatecancer
AT malkowiczstanleybruce continuityofcareandadvancedprostatecancer
AT gallojosephj continuityofcareandadvancedprostatecancer
AT chhatresumedha continuityofcareandadvancedprostatecancer